Last reviewed · How we verify
Vancomycin inhalation powder
Vancomycin inhalation powder works by inhibiting bacterial cell wall synthesis.
Vancomycin inhalation powder works by inhibiting bacterial cell wall synthesis. Used for Treatment of nontuberculous mycobacterial lung disease.
At a glance
| Generic name | Vancomycin inhalation powder |
|---|---|
| Also known as | AeroVanc |
| Sponsor | Savara Inc. |
| Drug class | glycopeptide antibiotic |
| Target | cell wall precursors |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Vancomycin is a glycopeptide antibiotic that binds to the D-alanyl-D-alanine terminus of cell wall precursors, preventing the formation of the bacterial cell wall. This ultimately leads to bacterial cell lysis and death.
Approved indications
- Treatment of nontuberculous mycobacterial lung disease
Common side effects
- Cough
- Dyspnea
- Nausea
Key clinical trials
- AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis (PHASE3)
- Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients (PHASE2)
- Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vancomycin inhalation powder CI brief — competitive landscape report
- Vancomycin inhalation powder updates RSS · CI watch RSS
- Savara Inc. portfolio CI